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Abstract
Background: Stromal fibroblasts participate in the development of a permissive environment for tumor growth,
yet molecular pathways to therapeutically target fibroblasts are poorly defined. CD248, also known as endosialin or
tumor endothelial marker 1 (TEM1), is a transmembrane glycoprotein expressed on activated fibroblasts. We
recently showed that the cytoplasmic domain of CD248 is important in facilitating an inflammatory response in a
mouse model of arthritis. Others have reported that CD248 gene inactivation in mice results in dampened tumor
growth. We hypothesized that the conserved cytoplasmic domain of CD248 is important in regulating tumor
growth.
Methods: Mice lacking the cytoplasmic domain of CD248 (CD248CyD/CyD) were generated and evaluated in tumor
models, comparing the findings with wild-type mice (CD248WT/WT).
Results: As compared to the response in CD248WT/WT mice, growth of T241 fibrosarcomas and Lewis lung
carcinomas was significantly reduced in CD248CyD/CyD mice. Tumor size was similar to that seen with CD248-
deficient mice. Conditioned media from CD248CyD/CyD fibroblasts were less effective at supporting T241
fibrosarcoma cell survival. In addition to our previous observation of reduced release of activated matrix
metalloproteinase (MMP)-9, CD248CyD/CyD fibroblasts also had impaired PDGF-BB-induced migration and expressed
higher transcripts of tumor suppressor factors, transgelin (SM22a), Hes and Hey1.
Conclusions: The multiple pathways regulated by the cytoplasmic domain of CD248 highlight its potential as a
therapeutic target to treat cancer.
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Background
In normal tissues, fibroblasts are the major cellular com-
ponent of connective tissue and are key participants in
maintaining homeostasis of the extracellular matrix
(ECM), regulating epithelial differentiation, inflammation
and wound healing. Fibroblasts not only synthesize the
major constituents of the ECM, but they release ECM-
degrading proteinases to assure normal matrix turnover
and function. Fibroblasts also secrete multiple growth
factors and support mesenchymal-epithelial interactions
via paracrine and juxtacrine signaling. Within the tumor
stroma, subpopulations of fibroblasts emerge and exhibit
an “activated” phenotype, whereupon they acquire
characteristics that can be distin guished from normal
fibroblasts and often portend a bad prognosis [1]. These
activated fibroblasts, also referred to as peritumoral fibro-
blasts, cancer-associated fibroblasts, reactive stromal
fibroblasts and tumor-associated fibroblasts, are charac-
terized by the expression of myofibroblast-like cell mar-
kers, including alpha smooth muscle actin (a-SMA) and
desmin, and secrete factors that generally promote cell
growth and proliferation (e.g. hepatocyte growth factor
(HGF), epidermal growth factor (EGF), vascular endothe-
lial growth factor (VEGF), insulin growth factor 2 (IGF2),
fibroblast-like growth factor 2 (FGF2), transforming
growth factor-beta (TGF-b), ECM-degrading proteinases
such as MMPs, cytokines such as tumor necrosis factor
(TNF)-aand interleukin (IL)-1b and chemokines [2-4].* Correspondence: emconway@exchange.ubc.ca
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Tumor-associated fibroblasts are believed to originate
from tissue-resident fibroblasts and mesenchymal stem
cells, by recruitment of bone marrow-derived cells from
the circulation [5] and/or by epithelial-to-mesenchymal
transition [6]. The mechanisms by which fibroblasts
become activated are not well-defined, although TGF-b,
EGF, platelet-derived growth factor (PDGF)-BB, FGF2,
reactive oxygen species, complement factors, and integ-
rins have all been implicated [7-9]. Although there are
major gaps in our understanding of the mechanisms by
which tumor-associated fibroblasts evolve, cell surface
markers that are specific to these cells are attractive
candidate targets for therapy.
CD248, also referred to as endosialin or tumor
endothelial marker 1 (TEM1), is a highly sialylated cell
surface glycoprotein [10-12] that has been shown to be
restricted to activated stromal and perivascular fibro-
blasts [13-16]}. During normal embryonic development,
CD248 is highly expressed [17,18], but by full-term,
CD248 has almost entirely disappeared. Postnatally,
expression is retained only in the endometrium, in bone
marrow fibroblasts and in the corpus luteum [11,15,19].
However, CD248 is frequently upregulated in tumors
[10,15,20], with particularly high expression in tumor
associated stromal fibroblasts in sarcomas [19] and pri-
mary and secondary brain tumors [21]. CD248 is also
expressed in human mesenchymal stem cells from bone
marrow, which may differentiate into tumor stromal
fibroblasts [22]. In breast cancer and neuroblastomas,
CD248 expression levels have been directly correlated
with tumor grade, invasiveness and poor prognosis
[23,24]. The physiologic importance of CD248 in cancer
progression and its potential utility as a therapeutic tar-
get is further highlighted by the finding that lack of
CD248 in mice results in resistance to the growth and
metastasis of some tumors [25]. Therefore, delineating
the hitherto unknown mechanisms by which CD248
regulates tumor growth is important for the develop-
ment of therapeutic strategies.
The human CD248 gene is intronless and encodes a
95-kDa multi-domain type I transmembrane protein of
757 amino acids [26]. The protein comprises an N-
terminal C-type lectin-like domain, a Sushi domain,
three epidermal growth factor (EGF)-like repeats, a
mucin-like region, a single transmembrane segment and
a 51 amino acid residue cytoplasmic tail with potential
sites for phosphorylation [27]. CD248 belongs to a
family of proteins containing C-type lectin-like domains
which have functions in cell adhesion and regulation of
inflammation [28,29].
Few analyses have been performed to elucidate the
mechanisms by which CD248 regulates tumor growth.
In vitro studies suggest that the extracellular region of
CD248 may interact with ECM proteins, thereby
facilitating activation of MMP-9, cell migration and
metastasis formation [30,31]. We recently demon-
strated that the highly conserved cytoplasmic domain
of CD248 mediates signals that regulate stromal fibro-
blast function in an experimental model of rheumatoid
arthritis [32] and hypothesized that it would play a
similarly important role in modulating tumor growth.
We show that lack of the cytoplasmic domain of
CD248 in transgenic mice results in reduced tumor
growth, with alterations in fibroblast signaling via
TGF-b, PDGF-BB, and Notch pathways, and establish-
ment of a pattern of gene expression favoring tumor
suppression. The findings extend previous reports of
the importance of CD248 in tumor growth and point
to the cytoplasmic domain of CD248 as a potential
therapeutic target in neoplasia.
Methods
Mice
Transgenic mice lacking CD248 (CD248KO/KO) or the
cytoplasmic domain of CD248 (CD248CyD/CyD) were
previously generated and genotyped as reported [32].
Mice were maintained on a C57Bl6 genetic background
and corresponding wild-type mice (CD248WT/WT), gen-
erated from siblings during breeding of the CD248
transgenic lines, were used as controls.
In vivo tumor models
Heterotopic implantation of Lewis Lung Carcinoma
(LLC) tumor fragments was performed as described in
[25]. Briefly, 0.5 × 106 LLC cells were injected subcuta-
neously (s.c.) into the right flank of 5-week-old
CD248WT/WT mice. After 20 days, mice were sacrificed
and tumors dissected and cut into 1 mm3 pieces. 6-7
week old mice were anaesthetized with isoflurane and
the cecum exteriorized via a small incision parallel to
the midline. A single tumor fragment was implanted on
the serosal surface of the cecum. Tumors were dissected
15 days after implantation, and tumor volume and
weight were measured. Volume was calculated using the
formula, length × width2 × π/6.
For T241 fibrosarcoma studies, 1 × 106 cells in 200 μL
PBS or 7.5 × 104 LLC cells in 50 μL PBS were injected
s.c. into the right flank or footpad of 7-9 week-old mice.
Tumor size was evaluated every 2 days using a caliper
and weights were obtained after dissection. Studies were
performed in a blinded manner to the investigator.
The model of orthotopic growth and metastasis of
pancreatic adenocarcinoma in mice was performed
exactly as reported [33]. Briefly, mice were anaesthetized
with isoflurane and the stomach exteriorized via an
abdominal midline incision. 1 × 106 PancO2 pancreatic
adenocarcinoma cells in 25 μL PBS were injected into
the head of the pancreas. At day 11, primary tumors
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were dissected, and tumor volume and weight were
determined.
Immunohistochemistry and quantification of tumor vessel
density
Tissue samples were fixed with 2% paraformaldehyde
overnight at 4°C, dehydrated and embedded in paraffin.
Serial 7 μm sections were cut for histological analysis.
Immunohistochemical detection was performed using
the following antibodies: rat anti-CD31 (BD Pharmin-
gen, Erembodegem, Belgium), mouse anti-SMA-Cy3
(Dako, Glostrup, Denmark), phospho-histone H3 (Cell
Signaling Technology, Bioké, Leiden, the Netherlands)
and rabbit anti-caspase 3 (Abcam, Cambridge, MA,
USA). Morphometric analyses were performed using a
Zeiss Imager Z1 or AxioPlan 2 microscope with KS300
image analysis software. For all studies, 6-8 optical fields
per tumor section, at 40× or 80× magnification, were
randomly chosen and analyzed. Cell proliferation was
calculated as the number of phospho-histone H3 per
mm2. Vessel density was calculated as the number of
CD31-positive vessels per mm2 and pericyte coverage as
the percentage of CD31-positive vessels that are covered
by SMA-positive cells. Vessel distribution was deter-
mined by calculating the frequency distribution of ves-
sels with different areas.
In vitro studies with murine embryonic fibroblasts
Murine embryonic fibroblasts were isolated from E13.5
embryos as previously reported [32]. Fibroblasts were
cultured in DMEM with 10% fetal calf serum (FCS) and
used at passages 2-5. To assess the response to exogen-
ous growth factors, 1.5 × 105 fibroblasts were seeded in
6-well plates. After 18 hours of serum-starvation, cells
were stimulated with 20 ng/mL recombinant rat PDGF-
BB (R&D Systems, Abingdon, UK) for 30 minutes or 3
ng/mL recombinant human TGF-b1 (R&D Systems) for
72 hours. To assess the role of direct contact of
endothelial cells, 1.5 × 105 fibroblasts were mixed with
an equal number of the human endothelial cell line,
EaHy926 [34] and cultured in DMEM containing 10%
FCS for 24 hours. Cells were finally processed for
reverse transcription PCR.
Murine embryonic fibroblast migration studies
2.5 × 104 fibroblasts were seeded in the upper chamber
of 8 μm-pore size transwells (Costar, Elscolab, Kruibeke,
Belgium). DMEM/1% FBS with or without 20 ng/mL
PDGF-BB was added to the bottom well to stimulate
migration. After 18 hours of incubation, cells were fixed
in 1% paraformaldehyde and stained with 0.5% crystal
violet solution. The number of migrated cells was quan-
tified by counting five high-power magnification fields
per transwell [14]. All studies were repeated with 3
independent clones of fibroblasts from each genotype,
yielding comparable results. Thus, representative results
were reported.
Tumor cell survival assays
5 × 103 T241 fibrosarcoma cells or PancO2 cells were
seeded in 96-well plates and serum-starved for 6 hours
before adding conditioned medium of murine embryo-
nic fibroblasts grown in DMEM containing 10% FCS or
stimulated with serum-free DMEM containing 3 ng/mL
recombinant human TGF-b1 for 24 hours. The number
of viable cells was determined 24, 48 and 72 hours after
using the CellTiter 96 Aqueous One Solution (Promega,
Leiden, The Netherlands) according to manufacturer’s
instructions.
Quantitative reverse transcription (qRT)-PCR
RNA was extracted from cells using Qiagen RNeasy kit.
0.5-1 μg of total RNA was used for reverse transcription
with QuantiTect Reverse Transcription kit (Qiagen, KJ
Venlo, the Netherlands). qRT-PCR was performed using
TaqMan Fast Universal PCR Master Mix (Applied Bio-
systems, Halle, Belgium) and commercially available or
home-made primers and probes for the genes of interest
(Table 1). Analyses were performed using ABI7500 Fast
Real-Time PCR System (Applied Biosystems, Halle, Bel-
gium). All experiments were performed a minimum of 3
times, each in at least triplicate.
Statistics
Data represent mean ± standard error of the mean
(SEM) of experiments performed at least in duplicate.
Statistical significance was calculated by t-test or two-
way ANOVA (Prism 5.0), with p < 0.05 considered sta-
tistically significant.
Animal care
All experimental animal procedures were approved by
the Institutional Animal Care and Research Advisory
Committee of the K. U. Leuven.
Results
The cytoplasmic domain of CD248 is required for the
growth of some tumors
Studies with CD248-deficient mice indicate that CD248
is necessary for tumor growth [25]. In an experimental
model of rheumatoid arthritis, we recently determined
that CD248KO/KO mice and mice lacking the cytoplasmic
domain of CD248 (CD248CyD/CyD mice) develop less
severe arthritis than CD248WT/WT mice, the differential
response likely due to alterations in synovial fibroblast
function [32]. Based on these data, we predicted that the
highly conserved cytoplasmic domain of CD248 would
mediate signals that critically contribute to tumor
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growth. To test this hypothesis, we first validated the
role of CD248 in tumor growth in CD248KO/KO mice,
comparing the response with corresponding CD248WT/
WT mice. T241 fibrosarcoma cells were injected s.c. and
tumor size was monitored. Over a period of 23 days,
tumors in the CD248KO/KO mice were significantly smal-
ler than in the CD248WT/WT mice (n = 6, p = 0.0009)
(Figure 1A). The findings are confirmatory of an impor-
tant role for CD248 in tumor growth.
We next assessed whether the cytoplasmic domain of
CD248 is required for growth of the T241 fibrosarco-
mas. We observed a significant reduction in tumor size
and tumor weight of s.c. T241 fibrosarcoma tumors in
the CD248CyD/CyD mice as compared to CD248WT/WT
mice (n = 6, p < 0.0001) (Figure 1B). In experiments
replicating the setup of Nanda and coworkers [25], we
also implanted LLC tumor fragments heterotopically on
the serosal surface of the cecum of CD248WT/WT or
CD248CyD/CyD mice. Again, CD248CyD/CyD mice devel-
oped tumors that were significantly smaller than in the
CD248WT/WT mice (n = 7, p < 0.05) (Figure 1C).
Notably, not all tumors were resistant to growth in the
CD248CyD/CyD mice, i.e. there were no differences in the
growth of primary orthotopic PancO2 pancreatic adeno-
carcinomas (Figure 1D) or after injection of LLC cells
into the footpads (Figure 1E). Thus, similar to what was
observed by others with CD248-deficient mice [25],
CD248 does not regulate the growth of all tumors.
Angiogenesis-independent reduced tumor growth in
CD248CyD/CyD mice
Although the dependence of tumor progression on
angiogenesis is well-documented [35], additional factors
also modify tumor growth, sometimes apparently inde-
pendent of new vessel growth [36,37]. This is relevant
to CD248, as two groups have reported a CD248-depen-
dent inverse relationship between microvessel density
and size of tumor. Tumors of the large intestine derived
from LLC cells [25] and intracranial glioblastomas
derived from U87MG cells [21] were reportedly smaller
in size and weight in CD248-deficient mice, yet these
tumors had higher vessel density than those in wild-type
mice. We assessed the role of the cytoplasmic tail of
CD248 in modulating the relationship between tumor
growth and angiogenesis by first examining vessel den-
sity in the s.c. T241 fibrosarcomas in CD248CyD/CyD and
CD248WT/WT mice at the end of the observation period.
Endothelial cell-specific CD31 staining of the tumors
revealed that vessel density was not significantly differ-
ent in tumors from CD248WT/WT and CD248CyD/CyD
mice (Figure 1F). We also did not detect differences
based on genotype when we stratified the results accord-
ing to the lumen area of the vessels (data not shown).
The number of vessels covered by SMA-positive peri-
cytes was also not affected by lack of the cytoplasmic
domain of CD248 (Figure 1G). Notably, we did not
observe an inverse relationship between vessel density
and tumor size in our studies with the CD248CyD/CyD
versus CD248WT/WT mice, findings that contrast with
those reported in studies using CD248-deficient mice
[21,25]. This prompted us to examine T241 tumor
angiogenesis in our CD248KO/KO mice, with the aim of
establishing whether the cytoplasmic domain is the
major determining factor. In spite of significantly smal-
ler tumors in the CD248KO/KO versus CD248WT/WT
mice at the time of sacrifice at Day 23 (Figure 1A), ves-
sel density and pericyte coverage of s.c. T241 fibrosarco-
mas in CD248WT/WT and CD248KO/KO mice were not
significantly different (endothelial-specific CD31 stain-
ing, vessels per mm2: 107 ± 18 vessels/mm2 in
CD248WT/WT versus 90 ± 8 vessels/mm2 in CD248KO/
KO; n = 7, p = 0.40; % vessels covered by smooth muscle
actin (SMA)-positive cells: 23.6 ± 5.3 in CD248WT/WT
versus 26.7 ± 3.1 in CD248KO/KO; n = 7, p = 0.619).
Overall, the preceding findings indicate that loss of
CD248 or its cytoplasmic domain results in an uncou-
pling of the link between tumor growth and vessel den-
sity, and that alterations in stroma-derived factors
regulated by CD248 may underlie the differences in
tumor growth.
Table 1 List of primers and probes used for qRT-PCR
Gene Forward Reverse Probe
Hes TCAGCGAGTGCATGAACGA CCTCGGTGTTAACGCCCTC TGACCCGCTTCCTGTCCACGTG
Gene Sequence ID (Commercially available primers)
b-actin Mm00607939_s1
CD248 Mm0054785_s1
Hey1 Mm00468865_m1
Jagged1 Mm00496902_m1
hJagged1 Hs01070028_g1
Notch3 Mm00435270_m1
SM22a Mm00441660_m1
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Cytoplasmic domain of CD248 modulates stromal
fibroblast function
Using murine embryonic fibroblasts as a model [38-40],
we recently established that in spite of having normal
antigen levels, fibroblasts from CD248CyD/CyD mice are
less adhesive to monocytoid cells and express lower
levels of placental growth factor (PlGF), VEGF, VEGF
receptor-1 (VEGFR-1) and matrix metalloproteinase
(MMP)-9 [32]. These findings are consistent with our
observation that the CD248CyD/CyD mice are resistant to
tumor growth, but suggest that there may be multiple
pathways by which the cytoplasmic domain of CD248
regulates fibroblast function to facilitate tumor progres-
sion. We therefore tried to uncover additional CD248-
dependent alterations in stromal fibroblasts that could
help to explain the smaller tumors in CD248CyD/CyD
mice.
a. Elevated expression of the tumor suppressor SM22a in
CD248CyD/CyD fibroblasts
Recent studies support the concept that activated stro-
mal fibroblasts co-evolve with tumor cells and that their
activation and survival is sustained in part by altered
expression of tumor suppressor genes [41,42].
Figure 1 Role of CD248 in tumor growth in mice. A. Growth of T241 tumors is significantly reduced in CD248KO/KO mice (n = 6, p < 0.001). B.
Growth of T241 tumors is significantly reduced in CD248CyD/CyD mice (n = 6, p < 0.001). C. LLC tumors implanted in the cecum are significantly
smaller in CD248CyD/CyD mice (n = 7, p < 0.05). D. PancO2 tumors grown orthotopically are not different in size in CD248WT/WT and CD248CyD/CyD
mice (n = 4, p = not significant). E. LLC tumor growth in the footpad is similar in CD248WT/WT and CD248CyD/CyD mice (n = 6, p = not
significant). F-G. Morphometric quantification reveals that there are no genotype-dependent differences in vessel density (F) or PC coverage (G)
(n = 7, p = not significant). Data represent the mean ± SEM. Asterisks denote statistical significance.
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Transgelin (SM22a) is a cytoplasmic actin-binding pro-
tein, expressed by mesenchymal cells and tumor fibro-
blasts [43] and which represses TGF-b-induced MMP-9
expression [44], reduces cell migration, and has tumor
suppressor properties [45]. We assessed whether expres-
sion of SM22a is dependent on the integrity of the cyto-
plasmic domain of CD248. Baseline transcript levels of
SM22a were significantly higher in CD248CyD/CyD fibro-
blasts as compared to CD248WT/WT fibroblasts (Figure
2). Transcript levels of SM22a in the CD248WT/WT
fibroblasts increased to a non-significant extent in
response to TGF-b. In contrast, the transcript levels of
SM22a, already elevated in the CD248CyD/CyD fibro-
blasts, increased further upon TGF-b stimulation to
levels significantly higher than in the TGF-b stimulated
CD248WT/WT fibroblasts. The findings indicate that the
cytoplasmic domain of CD248 participates in the sup-
pression of SM22a expression, providing a mechanism
to help explain reduced stromal cell activation, migra-
tion and MMP-9 release and thus, less tumor expansion
in the CD248CyD/CyD mice.
b. The cytoplasmic domain of CD248 facilitates PDGF-BB-
induced cell migration
With altered expression of SM22a, we hypothesized that
CD248CyD/CyD fibroblasts would also exhibit resistance
to factors that promote their migration in a tumor set-
ting. PDGF-BB is a potent chemoattractant for stromal
cells and a trigger for recruitment of tumor associated
fibroblasts (reviewed in [46]). Experimental evidence
supports a role for PDGF signaling in cancer progres-
sion, with rationale for targeting this pathway in tumor-
associated stromal fibroblasts [47,48]. Moreover, it has
been shown in some studies that fibroblasts require
CD248 for optimal migratory response [14,49]. To
determine whether the cytoplasmic domain of CD248
regulates PDGF-BB-induced cell migration, CD248WT/
WT and CD248CyD/CyD fibroblasts were stimulated to
migrate across transwells toward recombinant PDGF-
BB. In the absence of PDGF-BB, there were no differ-
ences in the number of migrated CD248WT/WT and
CD248CyD/CyD fibroblasts. For both genotypes, PDGF-BB
induced a significant increase in fibroblast migration in
a dose-dependent manner. However, at the two concen-
trations of PDGF-BB tested, CD248CyD/CyD fibroblast
migration was significantly less as compared to the
migration of CD248WT/WT fibroblasts (Figure 3). Over-
all, these data support the importance of the cytoplas-
mic domain of CD248 in facilitating PDGF-BB mediated
stromal fibroblast migration, a process that is important
in tumorigenesis.
c. CD248 suppresses Notch3 signaling and dampens Hes
and Hey1 gene expression
Although activation of Notch may promote cancer
development [50], Notch may also have a tumor sup-
pressor function, partly by promoting cellular differen-
tiation and maturation of mesenchyme derived
perivascular cells [51,52]. Notch signaling requires acti-
vation by the ligand Jagged1, which induces cleavage of
Notch3 and release of Notch intracellular domain
(NICD), nuclear translocation of which further activates
Notch3. This is accompanied by transcription of several
genes, including Hes, Hey1 and SM22a, all of which
may exhibit tumor suppressor properties [45,53,54].
Notch3 also feeds back and promotes Jagged1 expres-
sion in pericytes, thereby maintaining their differentiated
state [55].
Figure 2 CD248-dependent expression of SM22a. CD248CyD/CyD
fibroblasts express higher transcript levels of SM22a at baseline (n =
4, p < 0.0001) and after TGF-b stimulation for 72 hours (n = 4, p =
0.0004). Results reflect the mean ± SEM. Asterisks denote statistical
significance.
Figure 3 CD248 modulates PDGF-BB mediated cell migration.
A. Migration of fibroblasts across a transwell was quanitified as
described in Methods. PDGF-induced migration of CD248CyD/CyD
fibroblasts is significantly reduced as compared with CD248WT/WT
fibroblasts (n = 6). Results reflect the mean ± SEM. * p < 0.05; ** p
< 0.001.
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To determine whether the cytoplasmic domain of
CD248 alters Notch3 signaling, we measured genes
involved in the Notch pathway in isolated fibroblasts
and in fibroblasts that were co-cultured with equal
numbers of human EaHy926 endothelial cells. Baseline
levels of Notch3, Jagged1, Hes and Hey1 transcripts
were significantly increased in CD248CyD/CyD fibroblasts
as compared with CD248WT/WT fibroblasts (Figure 4),
indicating that Notch3 signaling and transcription of
Hes and Hey1 in isolated fibroblasts is dampened via
signals mediated by the cytoplasmic domain of CD248.
Human endothelial Jagged1 is known to induce
Notch signaling in murine fibroblasts [55] and the use
of different species cells in co-culture allowed us to
distinguish the cellular source of each gene. As
expected, contact of endothelial cells with CD248WT/
WT fibroblasts resulted in an increase in expression of
the transcripts for Notch3, Jagged1, Hes and Hey1
Figure 4 Effects of CD248 on Notch3 signaling. Baseline transcript levels of Notch3 (A), Jagged1 (B), Hes (C) and Hey1(D), are increased in
CD248CyD/CyD fibroblasts as compared with CD248WT/WT fibroblasts(n = 4, p = 0.0139 for Notch3; p = 0.0041 for Jagged1; p = 0.00067 for Hes; p
= 0.0051 for Hey1). Fibroblasts were also co-cultured with human EaHy926 endothelial cells for 24 hours (A-D), causing further upregulation of
the transcripts for both genotypes. E. Transcript levels of CD248 in CD248WT/WT and CD248CyD/CyD fibroblasts are significantly reduced to similar
levels after co-culture with EaHy926 endothelial cells (n = 4).
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(Figure 4). When CD248CyD/CyD fibroblasts were co-
cultured with endothelial cells, transcript levels of
Notch3, Jagged1, Hes and Hey1 also increased as com-
pared with fibroblasts alone. Responses were not
affected by changes in endothelial expression of
Jagged1, since Jagged1 was similarly upregulated in
endothelial cells co-cultured with either CD248CyD/CyD
or CD248WT/WT fibroblasts (copies of human Jagged1
per 1000 copies of b-actin: 740 + 70 in co-cultures
with CD248WT/WT fibroblasts versus 710 + 70 in co-
cultures with CD248CyD/CyD fibroblasts, n = 4, p = not
significant). Although Notch3, Hes and Hey1 gene
expression were still higher in CD248CyD/CyD fibroblast
than in CD248WT/WT fibroblasts in the co-culture con-
ditions, the differences did not achieve statistical sig-
nificance. We considered that this might be an in vitro
effect due to endothelial contact-induced differentia-
tion and maturation of the fibroblasts, which would
thus suppress CD248 expression and diminish the dif-
ferential effect of the absent cytoplasmic domain of the
molecule on Notch signaling. Indeed, under these co-
culture conditions, CD248 transcript levels were signif-
icantly reduced by >50% in both the CD248WT/WT and
CD248CyD/CyD fibroblasts (Figure 4E).
Taken together, the findings support the concept that
suppression of CD248 or interfering with signaling via
its cytoplasmic domain may be associated with increased
maturation of tumor stromal or perivascular fibroblasts
and expression of tumor suppressor genes.
CD248-dependent release of soluble factors from
fibroblasts modulates T241 tumor cell proliferation
The preceding studies underscore the role of the cyto-
plasmic domain of CD248 in modulating genes that regu-
late stromal fibroblast differentiation, maturation and
migration and the expression of tumor suppressor genes.
We recently reported that CD248CyD/CyD fibroblasts
express reduced amounts of VEGF, PlGF and active
MMP-9 [32] and considered that other soluble factors
might be secreted in a CD248-dependent manner that
regulate tumor cell proliferation. We therefore assessed
the effects of conditioned media (CM) from the fibro-
blasts of CD248WT/WT and CD248CyD/CyD on T241 fibro-
sarcoma cell proliferation. After 24 hours, tumor cell
viability with CM from the different genotype fibroblasts
was not significantly different (Figure 5A). However, at
48 hours and 72 hours, the number of T241 fibrosarcoma
cells exposed to CM from the CD248CyD/CyD fibroblasts
was significantly lower as compared to those exposed to
CM from the CD248WT/WT fibroblasts. Although there
appeared to be a similar CD248-dependent effect on
PancO2 cell survival, the differences did not achieve sta-
tistical significance (Figure 5B). These findings, which are
consistent with those observed in vivo, indicate that the
cytoplasmic domain of CD248 modulates the release of
factors from fibroblasts that differentially promote the
survival of specific tumor cells.
Discussion
CD248 was originally believed to be a tumor endothelial
cell marker, and thus referred to as endosialin or TEM1
[10-12]. CD248 is now recognized to be primarily
expressed on the surface of mesenchymal stem cells,
activated stromal fibroblasts and pericytes [16], cells
that may contribute to fibrovascular network expansion
and tumor progression [5]. While several investigators
have shown that CD248 plays an important role in
tumor growth and stromal expansion [13-15,21,25] with
expression levels that have been correlated with tumor
progression [23,24], the mechanisms by which CD248
functions and the key structural domains involved, have
remained a mystery. In our studies, we established that
the cytoplasmic domain of CD248 is a key regulator of
tumor growth and that mice lacking this domain are
resistant to growth of T241 fibrosarcoma tumors and
heterotopic LLC tumors.
Figure 5 CD248-dependent fibroblast release of trophic factors that regulate tumor cell survival. T241 fibrosarcoma cells (A) and PancO2
pancreatic adenocarcinoma cells (B) were grown in conditioned media (CM) from CD248WT/WT fibroblasts and CD248CyD/CyD fibroblasts and cell
viability was quantified at 24, 48 and 72 hours as described in Methods. At 48 hours (n = 3) and 72 hours (n = 6), the number of T241 cells
exposed to CM from the CD248CyD/CyD fibroblasts was significantly lower as compared to those exposed to CM from the CD248WT/WT fibroblasts.
No differences in viability were detected with the PancO2 cells. Data represent the mean ± SEM. * p < 0.05; ** p < 0.01.
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Activated fibroblasts dynamically interact with consti-
tuents of the stromal compartment and participate in
tumor progression via several mechanisms, including for
example, remodeling the ECM, promoting the recruit-
ment of inflammatory cells, enhancing nutritional sup-
port of the stromal microenvironment, and by secreting
an array of pro-lymph/angiogenic and autocrine and
paracrine acting cellular growth factors [6,56-58]. The
cytoplasmic domain of CD248 is a critical enabler for
stromal fibroblast activation, endowing the fibroblast
with several tumor-promoting properties. Tumor fibro-
blasts can achieve and maintain an activated state in the
tumor microenvironment by acquiring epigenetic and/or
genetic changes that mitigate the function of tumor sup-
pressor genes, such as p53 and PTEN in breast cancer
[41,42]. In this manner, activated fibroblasts can exhibit
a phenotype that favors proliferation and an enhanced
response to pro-survival and migratory cues released by
neighboring fibroblasts and other tumor and non-tumor
stromal cells. In this regard, we evaluated the relation-
ship between the cytoplasmic domain of CD248 and
SM22a, a tumor suppressor gene that when dysregu-
lated, is implicated in the progression and metastasis of
cancers of the colon, breast and prostate [45,59]. SM22a
was considered a likely candidate for CD248-dependent
expression because it is known to be upregulated by
TGF-b, and because we had previously shown that
CD248CyD/CyD fibroblasts release less TGF-b and are
resistant to TGF-b-mediated angiogenic and pro-inflam-
matory activities [32]. CD248CyD/CyD fibroblasts
expressed significantly higher transcript levels of
SM22a, further upregulated by TGF-b to levels exceed-
ing those seen with CD248WT/WT fibroblasts. Although
we have not directly determined whether SM22a dam-
pens activation of fibroblasts, it is reasonable to consider
that elevated levels might contribute to the smaller
tumors in the CD248CyD/CyD mice by maintaining the
fibroblasts in a more quiescent state and by indirectly
reducing TGF-b-induced MMP-9 release, overall pre-
venting microenvironmental changes that would facili-
tate cell migration and cancer progression.
Since SM22a is co-ordinately regulated by Notch and
TGF-b [60], we hypothesized that the cytoplasmic
domain of CD248 would similarly regulate expression of
Hes and Hey1, downstream effectors of Notch that also
exhibit context-specific tumor suppressor properties
[53,54]. Indeed, Hes and Hey1 transcript levels in
CD248CyD/CyD fibroblasts were significantly higher than
in CD248WT/WT fibroblasts, in line with the role of
CD248 in promoting tumor growth. Notably from these
studies, we uncovered a novel mechanism by which
fibroblast CD248 is itself regulated, i.e., it is markedly
suppressed by direct contact with endothelial cells.
Although the molecular mechanisms remain to be
clarified, identification of strategies to downregulate
CD248 will be important for the design of therapies to
reduce both tumor growth and inflammation.
In addition to the role of the cytoplasmic domain of
CD248 in imparting fibroblast sensitivity to the effects of
TGF-ba, our studies also show that this domain of
CD248 is crucial for optimal migratory response of acti-
vated fibroblasts to PDGF-BB. Our observations are in
line with recent reports showing that CD248-deficient
fibroblasts or pericytes also have defects in migration and
proliferation that may [14,61] or may not [49] depend on
PDGF-BB. The apparent discordant findings in the litera-
ture likely reflect differences in experimental approaches.
Studies by Tomkowicz et al. suggest that CD248 may
recruit Src/PI-3 Kinase and cFos pathways to enhance
PDGF-BB-induced signals emanating from the PDGF-
receptor [61]. Further study will be necessary to elucidate
the intracellular pathways responsible for the reduced
PDGF-BB induced CD248CyD/CyD fibroblast migration.
In exploring the mechanisms underlying increased
resistance to arthritis induction in CD248CyD/CyD mice
[32], we recently showed that CD248CyD/CyD fibroblasts
are less adherent to monocytes and express reduced
levels of VEGF, PlGF and VEGFR-1. These CD248-
dependent alterations serve to reduce leukocyte infiltra-
tion, synovial fibroblast migration, proliferation and
inflammation in arthritis [62,63]. The analogy between
cellular proliferation and metastasis formation in cancer
and synovial hyperplasia and invasion in rheumatoid
arthritis is well-recognized [64]. For that reason, and
because tumor associated macrophages also contribute
to cancer progression [4], we examined tumors from
CD248WT/WT and CD248CyD/CyD mice for leukocyte
infiltration (data not shown). There were, in fact, fewer
leukocytes in the tumors from CD248CyD/CyD mice
(1000 + 28 cells/mm2 in CD248CyD/CyD versus 1200 +
86 cells/mm2 in CD248WT/WT, n = 7, p = 0.0578),
although the differences were not statistically significant.
Nonetheless, the findings suggest that the cytoplasmic
domain of CD248 might also participate in the regulated
release by activated fibroblasts of pro-inflammatory fac-
tors such as IL-1b, monocyte chemotactic protein
(MCP)-1 and IL-8 [7], thereby further tipping the bal-
ance of the stromal microenvironment toward one that
favours tumor initiation and progression.
A striking observation made by investigators who pre-
viously evaluated CD248-deficient mice in tumor models
was the smaller tumor size associated with a seemingly
paradoxical increase in microvessel density [21,25]. In
spite of their finding that pericyte coverage was not
altered, Nanda et al. postulated that CD248-deficient
blood vessels may fail to mature properly, hence favor-
ing the sprouting of small-caliber vessels [25]. Surpris-
ingly, we did not observe any differences in vessel
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density or size distribution, nor in pericyte coverage in
T241 fibrosarcoma tumors from the CD248CyD/CyD mice
or CD248KO/KO mice. Several factors could explain why
the angiogenic responses were different in our studies
versus others, particularly for the CD248-deficient mice.
First and foremost, the xenograft tumor cell lines that
we examined were different from those of Nanda et al.
[25] and Carson-Walter et al. [21]. Second, one of the
groups [21] used immunodeficient mice for their xeno-
graft studies. Finally, the mice were exposed to different
environmental factors and were generated from distinct
genetic backgrounds. In spite of these differences, the
remarkable finding in the CD248CyD/CyD mice and the
CD248KO/KO mice (irrespective of the source) was that
tumor angiogenesis was not reduced, in spite of the
tumors being smaller than in their wild-type counter-
parts. This paradoxical lack of reduced tumor angiogen-
esis in the setting of smaller tumors is not without
precedent. For instance, Gas6-deficient mice grew smal-
ler tumors as compared to their wild type counterparts,
while microvessel density, vessel lumen area and peri-
cyte coverage did not change [37]. In that case, it was
determined that tumors cells induce infiltrating leuko-
cytes to produce the mitogen Gas6. Since CD248 is not
expressed by tumor cells, but rather by activated fibro-
blasts, it is interesting to note that conditioned media
from CD248CyD/CyD fibroblasts dampened the prolifera-
tive potential of T241 fibrosarcoma cells. Thus, it is
likely that the cytoplasmic domain of CD248 facilitates
fibroblast release of soluble factors that promote tumor
growth. Several candidates could be considered, includ-
ing for example, IGF-1, HGF and FGF, all of which
favor tumor cell survival and proliferation [2-4,65].
Interestingly, we and others have shown that not all
tumors depend on CD248 for growth. Moreover, the
same tumor does not necessarily progress in the same
CD248-dependent manner in different anatomical sites
[25]. Several groups have demonstrated that tumor
microenvironment and location functionally influence
tumor growth and metastasis. And tumor stromal het-
erogeneity may be associated with multiple factors
including differences in hypoxia-induced vascular
response [66], vessel maturation [67] and activation of
tumor associated fibroblasts [68]. Such heterogeneity
has considerable clinical relevance and may explain, at
least to some extent, unresponsiveness of some tumors
to anti-VEGF therapy [69]. The variable contribution of
CD248 to tumor growth highlights the importance of
understanding and establishing multiple targets for the
design of effective therapies for given tumors.
Conclusion
Overall, our studies confirm that CD248 is an important
central regulator of several critical pathways involved in
stromal fibroblast migration, proliferation and activation
that impact on tumor growth. Although we demonstrated
the importance of the cytoplasmic domain of CD248, a
structure that is highly conserved, with a PDZ binding
motif and potential sites for phosphorylation, no intracel-
lular interacting partners have yet been identified. Conver-
sely, others have shown that the ectodomain of CD248
does interact with components of the ECM, including col-
lagen, fibronectin and Mac-2 BP/90 K, and also partici-
pates in promoting tumor growth by modulating cellular
adhesion and migration and promoting the release of
MMP-9 [30,31]. It is likely that the intra- and extra-cellu-
lar domains of CD248 co-operate to achieve the same
functional endpoint, but the mechanisms and responsible
protein-protein interactions in the cell and outside the cell
remain to be determined. By gaining further insights, one
may ultimately consider therapeutic strategies to interfere
with CD248 signaling pathways to “normalize”, i.e. reverse
the genotype/phenotype of the tumor associated fibroblast,
thereby turning a tumor-permissive stromal environment
into a tumor-prohibitive one.
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